UAE Health Officials Mandate Lifestyle Overhaul Alongside Weight-Loss Drugs
Health authorities stress behavioral change as essential complement to pharmaceutical obesity treatment
Obesity treatment in the United Arab Emirates has entered a new era, but the clinical consensus is clear: GLP-1 weight-loss drugs are not enough on their own. The Dubai International Pharma and Technologies conference this week heard from leading medical advisers who stressed that medication must work alongside sustained behavioral change to produce lasting results.
The transformative potential of drugs such as Mounjaro and Wegovy has been widely acknowledged within the UAE health system. These medications suppress hunger hormones by mimicking the body’s natural appetite-regulating hormones, allowing patients to feel fuller for longer. The clinical picture emerging from the conference, however, suggests that prescribing these drugs without addressing underlying lifestyle factors represents incomplete treatment.
Dr Mohammad Fityan, group chief medical officer at Burjeel Holdings, made this position explicit during his remarks at the three-day conference on Wednesday. He described medication as delivering only a fraction of the solution. “The medicine will give you 50 to 60 per cent of the solution; the other 40 to 50 per cent is on the patient,” he said. That framing places significant responsibility on individuals to modify their behavior while taking the medication.
The evidence supporting this integrated approach is substantial. Patients who combine pharmacotherapy with lifestyle modifications demonstrate superior outcomes in both weight loss and weight maintenance compared to those relying on medication alone. Dr Fityan was direct: medication does not function as a standalone intervention. “If they change their lifestyle, they will lose weight and maintain that weight loss. Otherwise, this will not work.”
The scope of change required extends well beyond the conventional focus on diet and exercise. Dr Fityan identified sleep patterns, work schedules, and daily routines as equally important variables. “I always like the lifestyle, not just diet or exercise, but also when they go to sleep, for how many hours and also what shifts they work,” he noted. This reflects an understanding that obesity exists within broader behavioral and environmental systems.
Meanwhile, some insurance providers in the UAE have begun building mechanisms to reinforce this behavioral requirement. Certain reimbursement programmes now link coverage for obesity treatment to measurable physical activity targets. One such system connects patient step counts directly to electronic medical records, withholding reimbursement if daily activity falls below 10,000 steps. The structure aligns financial incentives with the behavioral expectations that medical evidence supports.
The potential health and economic benefits of effective obesity treatment in the UAE are considerable. Experts at the conference identified obesity as a defining public health challenge of this era, with global prevalence projected to reach 18 per cent by 2031. The UAE has historically recorded rates above that global average, creating elevated risk for chronic conditions that impose significant long-term costs on the health system.
A recent analysis by consultants Whiteshield and pharmaceutical manufacturer Eli Lilly examined what accelerated weight-loss programmes could mean for the UAE specifically. The report found that removing 1.2 million people from obesity could extend their healthy lifespan by 6.8 years. If an accelerated programme brought obesity rates from the current 32 per cent closer to the global average of 18 per cent, the health system could redirect approximately 1.5 billion dollars in expenditure away from treating obesity-related chronic conditions such as diabetes, cardiovascular disease, and cancer.
Dr Fityan noted that weight-loss medication combined with healthier habits could reduce the risk of hundreds of obesity-related conditions and potentially reverse Type 2 diabetes in some patients. Whether insurance structures and clinical programmes can reliably sustain the behavioral change that medication alone cannot produce remains the central question the UAE health system has yet to fully answer.
Q&A
What percentage of obesity treatment outcomes do medical officials attribute to medication versus patient behavioral change?
Dr Mohammad Fityan, group chief medical officer at Burjeel Holdings, stated that medication delivers 50 to 60 percent of the solution, with the remaining 40 to 50 percent dependent on the patient's behavioral modifications.
How are insurance providers in the UAE reinforcing behavioral requirements for obesity treatment coverage?
Certain reimbursement programmes now link coverage for obesity treatment to measurable physical activity targets, with one system connecting patient step counts directly to electronic medical records and withholding reimbursement if daily activity falls below 10,000 steps.
What are the projected economic benefits of reducing obesity rates in the UAE?
A Whiteshield and Eli Lilly analysis found that removing 1.2 million people from obesity could extend their healthy lifespan by 6.8 years, and reducing obesity rates from the current 32 percent to the global average of 18 percent could redirect approximately 1.5 billion dollars away from treating obesity-related chronic conditions.
What lifestyle factors beyond diet and exercise have health officials identified as important for obesity treatment?
Dr Fityan identified sleep patterns, work schedules, and daily routines as equally important variables, noting that when patients sleep, for how many hours, and what shifts they work are critical components of comprehensive lifestyle modification.